BOSTON SCIENTIFIC CORP BSX

About BOSTON SCIENTIFIC CORP (BSX): stock profile, AI score and financials

BOSTON SCIENTIFIC CORP (BSX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BSX at 77.3/100 on a composite quality score built from its SEC filings, placing it at rank #67 of 2,925 stocks — the top 5% of the AI-ranked universe. BSX scores in the top quartile across revenue scale (92.6), balance sheet strength (81.8), profitability (80.7). Shareholder dilution risk is elevated at 45.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BOSTON SCIENTIFIC CORP reports quarterly revenue of $5.4B, net income of $905.0M, an operating margin of 21.6%. Top institutional holders of BSX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. BSX trades on the NYSE exchange and files with the SEC under CIK 885725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BSX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BOSTON SCIENTIFIC CORP directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 885725 →